Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 3 | EJNMMI Radiopharmacy and Chemistry

Fig. 3

From: Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals

Fig. 3

Example of multimodality PET/MRI imaging providing several advantages in the context on non-clinical testing of radiopharmaceuticals. The use of anatomical information from MRI provides multiparameter longitudinal assessment in a preclinical model (A: native image (left) and blocked with excess target ligand (right)) with superior mapping of organs B for longitudinal biodistribution/blocking studies and delineation of uptake despite influence from renal excretion. Additionally biodistribution is calculated from the imaging data C (from Tshibangu et al. 2020, legend modified)

Back to article page